Karel Petrak

New concepts in drug targeting

Expert status:

12 month points:

Total points:

Awards earned
menu Summary

- generated safety, toxicity and efficacy preclinical data, and designed several clinical studies (mucositis, necrotizing enterocolitis, head and neck cancer, severe sepsis) which showed talactoferrin to be effective in Phase 2 clinical studies. - raised $10+ MM federal funds to support the above clinical studies.

- led development of gene-based products for asthma, rheumatoid arthritis, and transplant rejection project funded by Syntex (later Roche) with a total budget of $17 million. I filed patents for the electroporation and ultrasonic-nebulization technologies for gene delivery.

- managed a testing laboratory and a data management/statistics group (staff of 20, monitoring 5000+ studies) and streamlined stability testing to achieve 20% reduction of the overall work-volume and costs.

- developed self-assembling nanoparticles that avoided recognition by the reticulo-endothelial system of the body – a property essential for a systemic delivery of site-specific systems.

- developed and patented new photographic and electro resist materials, a surfactant-specific electrode, and a method for measuring diffusion of oxygen through coated polymer layers. I also developed polymer/polymer interactions and phase separation systems which found a major practical application in the company’s coating technology.

Published over 100 scientific publications and patents.

Specialties: Project leadership and management in all aspects of drug research and development.

work Experience

Chief Scientific Officer


February 2016 - Present

CSO guiding the company towards a successful submission of an Investigational New Drug designation for the company's lead compound.

In addition, is available for consulting services in the area of drug development and drug delivery, with special emphasis on site-selective / targeted delivery, covering pre-clinical, clinical and product-development phases.

VP for R&D

Agennix Inc.

July 2000 - September 2010

Leading development of a new immunomodulating-protein product from preclinical to successful Phase 2 clinical study in adult and neonatal sepsis.

Director and Program Head

Gene Medicine

September 1994 - August 1999

Leading multidiscipline projects, in a matrix system, gene-therapy projects in a number of indications.



September 1999 - September 2000

Leading gene-therapy product development to treat lung injury.

Research Area Head

Ciba-Geigy / Novartis

August 1985 - October 1993

Leading multidisciplinary projects in advanced drug delivery